Ptc Therapeutics, Inc.

Pct Therapeutics, Inc.

Harry H Miao

Liangxian Cao

Marla L Weetall

Langdon Miller

Thomas W Davis

Samit Hirawat

Jeff Campbell

William Lennox

Young-Choon Moon

Neil Gregory Almstead

Jeffrey Allen Campbell

Soongyu Choi

Hongyan Qi

Peter Seongwoo Hwang

William Jospeh Lennox

Christopher Robert Trotta

Charles Romfo

Donald Thomas Corson

Zhengxian Gu

Jason D Graci

Tamil Arasu

Thomas Davis

Maria L Weetall

Compounds, such as compounds of Formula (I), that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments. 

Methods for treating cancer and non-neoplastic conditions

Methods for treating prostate cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described. Methods for treating benign prostatic hyperplasia involving the administration of a compound that selectively inhibits pathological production of human VEGF are also described. The compound may be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.

Methods for treating prostate conditions

Methods for treating Kaposi's sarcoma involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.

Methods for treating Kaposi sarcoma

Growing community of inventors

Wellsley, MA, United States of America

Harry H Miao